Collectively, the results suggested that YTHDF2 could be a potential biomarker for predicting MM prognosis, and the combination of YTHDF2 with clinical features could effectively improve the accuracy of prognosis evaluation. Here, YTHDF2 is linked to Miyoshi myopathy.